Common Contracts
6 similar Employment Agreement contracts by 2seventy Bio, Inc., Candel Therapeutics, Inc., Cullinan Oncology, Inc., others
Nicola Heffron RE: Executive Agreement with 2seventy bio Dear Nicola, Nicola Heffron (“Nicola” or “you”) entered into an employment agreement with bluebird bio, Inc. (“bluebird”) dated October 22, 2019 (the “Existing Agreement”). On November 4, 2021,...Employment Agreement • March 22nd, 2022 • 2seventy Bio, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made between 2seventy bio, Inc. (the “Company”), and [______] (the “Executive”). Except for the Preserved Obligations (as defined below), this Agreement supersedes in all respects all prior and contemporaneous agreements, representations and communications between the Executive and the Company, and between the Executive and bluebird bio, Inc. (“bluebird”), regarding the employment of the Executive with either the Company or bluebird, including without limitation the Employment Agreement between the Executive and bluebird dated [___________] (including any amendments, the “Prior Employment Agreement”). In entering into this Agreement, in consideration for the opportunity to receive the compensation and benefits provided herein, the Executive hereby waives any right or potential right the Executive may have to receive: (i) any severance or change in control compensation or benefits under the Prior Employment Agreement, under any bluebird severan
EMPLOYMENT AGREEMENTEmployment Agreement • October 18th, 2021 • Cullinan Oncology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Cullinan Oncology, Inc., a Delaware corporation (the “Company”), and Nadim Ahmed (the “Executive”) and is effective as of the Executive’s first day of employment with the Company, which will be October 18, 2021 (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation any term sheet.
EMPLOYMENT AGREEMENTEmployment Agreement • August 13th, 2021 • Tango Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made between Tango Therapeutics, Inc., a Delaware corporation (the “Company”), and (the “Executive”) and is effective as of the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 13, 2021, by and among BCTG Acquisition Corp., BCTG Merger Sub Inc. and the Company (the “Effective Date”). Except with respect to the Equity Documents (as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • July 16th, 2021 • Candel Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Advantagene, Inc., a Delaware corporation d/b/a Candel Therapeutics (the “Company”), and Paul Peter Tak, M.D. Ph.D. (the “Executive”) and is made effective as of September 12, 2020 “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • July 7th, 2021 • Nuvalent, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made between Nuvalent, Inc., a Delaware corporation (the “Company”), and (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the [Employment Agreement]/[offer letter] between the Executive and the Company dated (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • December 28th, 2018 • Tcr2 Therapeutics Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made by and between TCR2 Therapeutics Inc., a Delaware corporation (the “Company”), and (the “Executive”), and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Equity Documents and the Restrictive Covenants Agreement (each as defined below) and subject to Section 10 below, this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation any offer letter, employment agreement or severance agreement.
